Research & Innovation Services

Newly Awarded KTP with Bath ASU

The University of Bath has been awarded a new KTP with Bath ASU, providers of aseptic manufacturing services to over 150 hospitals in the UK, for new product development towards applying extended shelf lives to intravenous cancer therapies.

It is currently not possible to evaluate the effect of extended storage for antibody drug conjugates (ADCs), which represent the next generation of cancer therapies.

Dr Andrew Watts, Pharmacy and Pharmacology, will lead the KTP in providing specialist academic knowledge of the chemical complexity of this drug class to extend the shelf lives for ADCs, enabling Bath ASU to batch manufacture many doses together, reducing waste, improving product quality, and increasing supply to the NHS.

Dr Watts says: "As a researcher, it is always gratifying to see your results translated into practice. Our partnership with Bath ASU has already generated a real impact with a number of new drug products coming onto the market. We now look forward to this continuing in the area of ADCs as a result of this recent award.”

Chris Watt, Director of Support Services at Bath ASU, says: “We are delighted to be building on our existing collaboration with the University of Bath, the Knowledge Transfer Programme will further facilitate an exchange of knowledge and technical skills between our two organisations in developing the next generation of intravenous patient cancer therapies.”

Bath ASU logo

Further information on Bath ASU

For further information on KTPs please contact:

Clive Bailey
Business Development Manager
Tel: +44 (0)1225 38 5201